Alpha-1-antitrypsin - Shire

Drug Profile

Alpha-1-antitrypsin - Shire

Alternative Names: Alpha 1-antitrypsin - Shire; Aralast; Aralast NP; Respitin

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Alpha Therapeutic Corporation
  • Developer Shire
  • Class Acute-phase proteins; Alpha globulins; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alpha 1-antitrypsin deficiency

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 15 Mar 2016 Biomarkers information updated
  • 26 Nov 2004 Data presented at the 70th Annual Meeting of the American College of Chest Physicians (CHEST-2004) have been added to the Respiratory Tract Disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top